High molecular weight amyloid β

Alzheimer Disease / metabolism Amyloid beta-Peptides / chemistry Calcium / metabolism Cell Line, Tumor Cell Membrane / drug effects Electrophysiology Hippocampus / drug effects Humans Lipid Peroxidation / drug effects Membrane Fluidity Microscopy, Atomic Force Molecular Weight Patch-Clamp Techniques Reactive Oxygen Species / metabolism
Alzheimer disease amyloid β-protein membrane disruption

Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
08 2019
Historique:
pubmed: 16 5 2019
medline: 2 6 2020
entrez: 16 5 2019
Statut: ppublish

Résumé

Amyloid β-protein (Aβ) molecules tend to aggregate and subsequently form low MW (LMW) oligomers, high MW (HMW) aggregates such as protofibrils, and ultimately fibrils. These Aβ species can generally form amyloid plaques implicated in the neurodegeneration of Alzheimer disease (AD), but therapies designed to reduce plaque load have not demonstrated clinical efficacy. Recent evidence implicates amyloid oligomers in AD neuropathology, but the precise mechanisms are uncertain. We examined the mechanisms of neuronal dysfunction from HMW-Aβ

Identifiants

DOI: 10.1096/fj.201900604R PMID: 31084283
pubmed: 31084283
doi: 10.1096/fj.201900604R
doi:

Substances chimiques

Amyloid beta-Peptides 0
Reactive Oxygen Species 0
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9220-9234

Auteurs

Taro Yasumoto (T)

Division of Neurology, Department of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan.
Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.

Yusaku Takamura (Y)

System Emotional Science, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.

Mayumi Tsuji (M)

Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.

Takahiro Watanabe-Nakayama (T)

World Premier International Research Center Initiative (WPI)-Nano Life Science Institute, Kanazawa University, Kakuma-machi, Kanazawa, Japan.

Keiko Imamura (K)

Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
iPSC-based Drug Discovery and Development Team, Riken BioResource Research Center (BRC), Kyoto, Japan.
Medical-risk Avoidance based on iPS Cells Team, Riken Center for Advanced Intelligence Project (AIP), Kyoto, Japan.

Haruhisa Inoue (H)

Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
iPSC-based Drug Discovery and Development Team, Riken BioResource Research Center (BRC), Kyoto, Japan.
Medical-risk Avoidance based on iPS Cells Team, Riken Center for Advanced Intelligence Project (AIP), Kyoto, Japan.

Shiro Nakamura (S)

Department of Oral Physiology, School of Dentistry, Showa University, Tokyo, Japan.

Tomio Inoue (T)

Department of Oral Physiology, School of Dentistry, Showa University, Tokyo, Japan.

Atsushi Kimura (A)

Division of Neurology, Department of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan.
Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.

Satoshi Yano (S)

Division of Neurology, Department of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan.

Hisao Nishijo (H)

System Emotional Science, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.

Yuji Kiuchi (Y)

Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan.

David B Teplow (DB)

Department of Neurology, David Geffen School of Medicine at the University of California-Los Angeles (UCLA), Los Angeles, California, USA.

Kenjiro Ono (K)

Division of Neurology, Department of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › High molecular weight amyloid β
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › High molecular weight amyloid β
questionsmedicales.fr › Facteurs biologiques › Facteurs de la coagulation sanguine › Calcium › High molecular weight amyloid β
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › High molecular weight amyloid β
questionsmedicales.fr › Cellules › Structures cellulaires › Membrane cellulaire › High molecular weight amyloid β
questionsmedicales.fr › Disciplines des sciences naturelles › Disciplines des sciences biologiques › Physiologie › Électrophysiologie › High molecular weight amyloid β
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex cérébral › Hippocampe › High molecular weight amyloid β
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › High molecular weight amyloid β
questionsmedicales.fr › Métabolisme › Métabolisme énergétique › Oxydoréduction › Peroxydation lipidique › High molecular weight amyloid β
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Fluidité membranaire › High molecular weight amyloid β
questionsmedicales.fr › Techniques d'investigation › Microscopie à sonde à balayage › Microscopie à force atomique › High molecular weight amyloid β
questionsmedicales.fr › Phénomènes chimiques › Masse moléculaire › High molecular weight amyloid β
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Techniques de patch-clamp › High molecular weight amyloid β
questionsmedicales.fr › Produits chimiques inorganiques › Composés de l'oxygène › Espèces réactives de l'oxygène › High molecular weight amyloid β